stocks logo

TAK Stock Price & Analysis

Takeda Pharmaceutical Co Ltd
$
14.925
+0.645(+4.517%)6M

TAK Stock Price Chart

5D
1M
3M
6M
YTD
1Y
5Y

TAK Fundamental Analysis

1
buy
Moderate Buy
Buy
Hold
Sell
bubble
High
36.48
bubble
Averages
36.48
bubble
Low
36.48
Analyst
Rating
Action
Price Target
Date
Rating Reason
TD Cowen
Ken Cacciatore
Buy
Maintains
$30 → $20
2023-05-16
TD Cowen
Ken Cacciatore
Buy
Maintains
$24 → $30
2023-04-04
B of A Securities
Koichi Mamegano
Hold
Strong Buy
Upgrades
$20
2023-03-16
Cowen & Co.
Ken Cacciatore
Hold
Buy
Upgrades
$21 → $24
2022-07-19

TAK Earnings Analysis

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share o Corporation (TAK.N) Q2 2025 Earnings Conference Call

Positive

  • Revenue Growth Highlights: First half revenue grew 5% at constant exchange rate, driven by our Growth & Launch product, which grew 18.7% at constant exchange rate and now accounts for 47% of total revenue.

  • Core Operating Profit Margin: Core operating profit margin was 30.2%, benefiting from product mix, phasing of R&D investment as well as the early impact of our efficiency programs.

  • Operating Cash Flow Increase: Operating cash flow was ¥451.3 billion, up 54.9% year-on-year, reflecting our strong profit growth as well as improvements in working capital.

  • Strong Growth in Product Portfolio: We achieved robust performance broadly across our Growth & Launch product portfolio, demonstrating significant growth at 18.7% at CER in the first half.

  • Product Launch Success: We have seen a strong uptake in our newly launched products, exceeding revenue expectations, and approvals in the European Union and Japan support the geographic expansion of these new treatments.

Negative

  • VYVANSE Sales Decline: VYVANSE declined 29% in the U.S. and 18% globally, indicating slower-than-expected erosion in the U.S.

  • Operating Profit Margin Analysis: Core operating profit margin was 30.2%, benefiting from product mix and R&D phasing, but still reflects challenges in cost management.

  • R&D Investment Decline: R&D investment decreased by 8.3% at CER, primarily due to the termination of certain programs during the pipeline privatization at the end of FY '23.

  • Operating Profit Surge: Operating profit was ¥350.6 billion, growing almost 200%, but this was influenced by less impairment and other one-time costs compared to the last fiscal year.

  • Liquidity Concerns Amid Profit Growth: Adjusted free cash flow was ¥247.5 billion, indicating potential liquidity issues despite strong operating profit growth.

TAK News

bubble
4.0
03-27Benzinga
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
bubble
8.0
03-21Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
bubble
4.0
03-10Business Insider
Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Oncolytics Biotech (ONCY)
bubble
9.0
03-03Benzinga
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
bubble
9.0
03-03Newsfilter
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

TAK FAQs

Should I buy or sell TAK Stock?

TAK stock is currently trading near its 52-week high with mixed analyst sentiment and recent positive study results, suggesting caution. Consider holding or waiting for a pullback before buying.

What is price prediction 2025 for TAK Stock?

What is surpport and resistant level for TAK Stock?

What is the current price of TAK Stock?

What is the target price of TAK Stock?

What is the market cap of Takeda Pharmaceutical Co Ltd?

Is Takeda Pharmaceutical Co Ltd (TAK) overvalued?

What is Takeda Pharmaceutical Co Ltd (TAK)'s business?

What is price prediction 2030 for TAK Stock?

How many employees does TAK have?

TAK Key Stats

High
15.060
Vol
577.98K
Low
14.900
Amount
8.65M
Open
15.000
VWAP
14.97
Mkt Cap
23.71B
EV/EBITDA(TTM)
9.22

TAK Company Profile

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.